Targeted control, transport, and measurement of biological processes

Functionalized biomaterials, modular nanorobots, and highly sensitive cell sensors share a common goal: they enable the targeted manipulation and transport of biological functions, as well as the analysis of biological reactions. For developers in the field of medical technology, this creates new opportunities to specifically influence cells and tissues, deliver active substances more precisely to their target sites, and evaluate biological reactions in real time. Recent research from Germany, Switzerland, and the United States demonstrates how these technologies could lay the foundation for new diagnostic and therapeutic applications.

Researchers at Fraunhofer IGB have developed a platform that allows for the targeted chemical modification of gelatin. This allows properties such as viscosity, solubility, charge, and cross-linkability to be tailored to different applications.

In bioprinting, the material plays an active role: The modified gelatin serves as a structural scaffold for cells and supports their adhesion, growth, and differentiation. In the EU project TriAnkle, it was used, among other things, as a carrier system for cells and growth factors. Furthermore, the material is also suitable for diagnostic applications. In a point-of-care rapid test, functionalized gelatin hydrogels were able to embed reaction components and specifically bind target molecules.

The key to medical application and subsequent industrial use is reproducible manufacturing. Automated reactor systems enable the standardized production of larger quantities of material with defined properties. This can serve as an important foundation for integrating biomaterials with consistent properties into applications such as tissue replacement, regenerative therapies, or diagnostic systems, and for their reliable validation.

While functionalized biomaterials influence biological environments, nanorobots are expected to intervene even more directly in cellular processes in the future. Researchers at the University of Basel have developed a modular system for this purpose, consisting of a magnetic propulsion module and an interchangeable payload capsule.

The payload can transport enzymes or other active substances and deliver them specifically to certain cell types. In the laboratory, the team succeeded in attaching the nanorobots to cancer cells and locally producing a therapeutically active substance there. This significantly reduced the viability of the cells under study.

This approach demonstrates how such systems could perform therapeutic functions in the future by specifically influencing biological processes at the target site and adapting to various applications through different payloads. According to the researchers, the platform’s modular design makes it relatively easy to configure for further medical or industrial applications.

To assess the effects of such biological interactions, new analytical methods are needed. Researchers at Harvard SEAS have developed a pico-calorimeter capable of detecting even the smallest thermal signals from living cells.

The microfluidic sensor measures metabolic activity directly and in real time. It can be used to monitor even small bacterial populations, as well as changes following the addition of antibiotics. Unlike many established methods, it analyzes the metabolic heat actually generated rather than indirect markers. This allows biological reactions to become visible earlier and provides researchers and development teams with immediate functional feedback.

Whether functionalized biomaterials, modular nanorobots, or highly sensitive cell sensors, these developments share a common goal. Medical technology systems are designed not only to monitor biological processes but also to directly influence them and make their reactions immediately measurable. This leads to new technological foundations for diagnostics, drug delivery, and regenerative applications.

Sources: Harvard School of Engineering and Applied Sciences, Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB, University of Basel